Well, shame on me, I haven’t seen the wood for the trees: The procedural decision in the matter O2016_003 (reported here) obviously relates to the suit filed by Illumina and Verinata Health against Genoma; see this Blog here.
“EP 000” is EP 0 994 963 B2. Opposition/appeal proceedings have been concluded with decision T 0146/07; see EPO Register for details.
“EP 111” is EP 1 981 995 B1. The hearing before the OD is scheduled for 18 November 2016; see EPO Register for details.
“EP 222” is EP 2 183 693 B1. The hearing before the OD is scheduled for 08 June 2016; see EPO Register for details. [UPDATE 29 July 2016: The OD has decided to maintain the patent in amended form on the basis of the first auxiliary request.]
“EP 333” is EP 2 514 842 B1 which has only been granted on 24 February 2016; see EPO Register for details.
Reported by Martin WILMING
Anti-competitive conduct is an issue, too, at least in UK proceedings; see here: https://www.genomeweb.com/business-policy-funding/european-commission-investigating-illumina-sequenom-anticompetitive-conduct